



SHUKRA

PHARMACEUTICALS LTD.

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

27th October, 2023

Scrip Code: 524632

Dear Sir/Madam,

Sub: Intimation of Board Meeting pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on **Wednesday, November 08, 2023** at the Registered Office of the Company to consider and approve the following: -

1. Unaudited financial result for the quarter and half year ended on September 30, 2023 along with the Limited Review Report of the Auditor pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.
2. Any other business with the permission of Chairman.

In terms of the Company's Code of Conduct for Prevention of Insider Trading, the "Trading Window" for dealing in securities of the Company has been closed from October 01, 2023 till the end of 48 hours after the declaration of the Financial Results of the Company for the quarter and half year ended on September 30, 2023.

You are requested to take the above information on records and disseminate the same.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited

Bhoomiben Patel
Director
DIN: 08316893



CIN : L24231GJ1993PLC019079